Potřebujete pomoc nebo informace a nevíte přesně na koho se obrátit?Kontaktujte nás
The well-established Laboratory Consortium for Research in Haematooncology and Stem Cells, under the leadership of Prof. Tomáš Stopka, announces a call for 2 candidates for PhD studies. The laboratories are located in BIOCEV - a scientific centre of excellence in biotechnology and biomedicine equipped with state-of-the-art instruments and facilities, which brings together top teams of erudite scientists from institutes of the Czech Academy of Sciences and two faculties of Charles University.
Two PhD projects have been announced:
1. the Leukaemia Research Project, which aims to identify tumour-specific genetic, proteomic and metabolic mechanisms that lead to the development of resistance and failure of anticancer therapy. The student will develop expertise in transformed cell culture, tumour growth in a mouse model, use of primary patient samples, multi-omics techniques and their integration. This will result in futuristic insight into the molecular pathways that determine the resistant phenotype of cancer cells. The PhD project will be carried out in close contact with the 1st Internal Medicine Clinic of the General University Hospital in Prague and the Czech Centre for Phenogenomics in Biocev.
2. The project focuses on Epigenetics in Stem Cells with the aim to understand the establishment of expression profile in differentiating progenitors at the level of DNA remodelling in chromatin. The broader goal is to understand the mechanisms involved in the development, growth and maintenance of tissue-specific stem cells and progenitors throughout the life of the organism. The successful candidate will generate and utilize transgenic animal models with mutations in regulators of chromatin remodelling and high-throughput methods to identify the localization of chromatin remodelling sites and transcription factor binding sites throughout the genome that influence the repression and activation of transcription factor pathways and their transcriptional targets required for normal and tumour development.
The deadline for applications is December 15, 2022 with a start date of early March 2023.